FDA and EU approvals ADC Therapeutics has an approved and marketed ADC product, ZYNLONTA, with accelerated FDA approval and conditional EU approval for relapsed or refractory DLBCL, indicating strong regulatory credibility and potential for expansion into additional indications and combination therapies.

Expansion and partnerships With a global commercial focus, established manufacturing and clinical capabilities, and ongoing IND-enabling programs for next generation PSMA-targeting ADCs, there are opportunities to pursue strategic collaborations, licensing, or co-development deals to broaden their ADC platform.

Financial runway Significant funding and revenue signals, including a $60M PIPE in 2025, a total funding level of about $1B, and reported Q4 2024 product revenue, suggest capacity for business development negotiations around in-licensing, payer strategy partnerships, and market access initiatives.

Market momentum Recent competitive landscape notes place ADC Therapeutics among peers actively refining linker and payload strategies; this presents an opportunity to position complementary or differentiated technologies, such as novel linker/payload chemistries or analytical tools, to address resistance and safety concerns.

Operational adjustments Headcount reductions and site consolidations in 2025–2026 indicate a strategic shift in operations; this could open doors for services, contract manufacturing, CRO/CMO partnerships, and collaborative R&D engagements to support cost-effective development and commercialization efforts.